Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the Aristotle randomized clinical trial

JAMA Cardiology

Volumn 1, Issue 4, 2016, Pages 451-460

  Hijazi, Ziad ^a,h   Hohnloser, Stefan H ^b   Andersson, Ulrika ^a   Alexander, John H ^c   Hanna, Michael ^d   Keltai, Matyas ^e   Parkhomenko, Alexander ^f   López Sendón, José L ^g   Lopes, Renato D ^c   Siegbahn, Agneta ^a   Granger, Christopher B ^c   Wallentin, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GOETHE UNIVERSITY   (Germany)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; CREATININE; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; DRUG EFFECT; KIDNEY; KIDNEY DISEASE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; TREATMENT OUTCOME; WARFARIN;

EID: 85008459351     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.1170     Document Type: Article

References (23)

1. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
2. Hart RG, Pearce LA, AguilarMI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
3. January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130 (23):2071-2104.
4. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet. 1989;1(8631):175-179.
5. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19): 2387-2394.
6. Go AS, Fang MC, Udaltsova N, et al; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009; 119(10):1363-1369.
7. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961-970.
8. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830.
9. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2013; 34(27):2094-2106.
10. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
11. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis InMyocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-641.
12. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 981-992.
13. Lopes RD, Alexander JH, Al-Khatib SM, et al; ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J. 2010;159(3):331-339.
14. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
15. Madder RD, Hickman L, Crimmins GM, et al. Validity of estimated glomerular filtration rates for assessment of baseline and serial renal function in patients with atherosclerotic renal artery stenosis: Implications for clinical trials of renal revascularization. Circ Cardiovasc Interv. 2011;4(3): 219-225.
16. Rossignol P, Cleland JG, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients aftermyocardial infarction: Insights from the Eplerenone Post-AcuteMyocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2012;125(2):271-279.
17. Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013;168(5):4678-4684.
18. Roldán V, Marín F, Fernández H, et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111(8):1159-1164.
19. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57(12): 1339-1348.
20. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009; 20(4):705-711.
21. Shlipak MG, Stehman-Breen C, Fried LF, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004; 43(5):861-867.
22. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17 (10):1467-1507.
23. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: An analysis from the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-2493.